Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
alanine aminotransferase/nàusea
L'enllaç es desa al porta-retalls
Pàgina 1 des de 339 resultats
Effects of ondansetron and granisetron on postoperative nausea and vomiting in adult patients undergoing laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled clinical trial.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Postoperative nausea and vomiting (PONV) are common and potentially distressing adverse events (AEs) associated with surgery and anesthesia. In patients undergoing laparoscopic cholecystectomy (LC) without antiemetic prophylaxis, the incidence of PONV can be as high as 72%.
OBJECTIVE
The
Radiology case of the month. Nausea, vomiting, and diarrhea in a patient with hepatitis C and acquired immunodeficiency syndrome (AIDS). Diffuse, severe gastric-wall thickening, consistent with edema.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The patient is a 42-year-old male with a past medical history of HIV/AIDS (his most recent CD4 count, four months before admission, was 19) and hepatitis C who presented to the Emergency Department complaining of one week of persistent nausea, vomiting, and diarrhea. His admit labs were as follows:
Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT(3))-receptor antagonist that has shown better efficacy than ondansetron and dolasetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy, and similar
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of cisplatin-induced emesis.
METHODS
This multicenter study was a stratified, randomized, double-blind, and parallel group design.
A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
To compare efficacy and safety of tacrine hydrochloride with placebo in patients with probable Alzheimer's disease.
METHODS
A 12-week, double-blind, placebo-controlled, parallel-group study.
METHODS
Outpatients at 23 centers.
METHODS
Men and women with probable Alzheimer's disease, at
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection.
OBJECTIVE
To determine the rates of sustained virologic response (SVR) in patients receiving the 3-drug combination of
Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
The aim of this observational study was to investigate the safety and efficacy of tolcapone under practice conditions.
METHODS
This 12-month non-interventional study was conducted from November 2005 to August 2009. Safety parameters were incidence of adverse drug reactions (ADRs), signs
A diffusely enlarged pancreas: the (un)usual suspect.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
An 81-years-old female presented with obstructive jaundice and a non-specific clinical picture of nausea and appetite loss. Labs demonstrated a conjugated hyperbilirrubinemia (7.7 mg/dL), increased aspartate aminotransferase and alanine aminotransferase (10xULN and 8xULN, respectively), increased
Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The purpose of this report is to describe the overall safety profile of both short- and longer-term duloxetine treatment of fibromyalgia. Data from four double-blind, randomized, placebo-controlled studies (two with 6-month open-label extension phases) and a 1-year, open-label safety study were
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
On October 24, 2019, a marketing authorization valid through the European Union (EU) was issued for gilteritinib monotherapy for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an Fms-like tyrosine kinase 3 (FLT3) mutation. Gilteritinib inhibits FLT3 receptor
Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
We evaluated the maximum tolerated dose (MTD) and safety of sunitinib plus capecitabine/cisplatin (XP) or capecitabine/oxaliplatin (XELOX) in Korean patients with advanced gastric cancer (GC).
METHODS
Sunitinib (37.5 or 25 mg/day) was administered on a 2-week-on/1-week-off schedule with
The addition of mycophenolate mofetil for suppressing hepatitis B virus replication in liver recipients who developed lamivudine resistance--no beneficial effect.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Mycophenolate mofetil is used as an immunosuppressive agent in liver transplant recipients. Its active compound, mycophenolic acid, also inhibits the replication of Epstein-Barr virus and human immunodeficiency virus. Based on a study indicating the effectiveness of mycophenolate mofetil
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
